Logo-bi
Bioimpacts. 2022;12(1): 51-55. doi: 10.34172/bi.2021.22167
PMID: 35087716        PMCID: PMC8783077

Original Research

Mesenchymal stromal cell therapy alone does not lead to complete restoration of skin parameters in diabetic foot patients within a 3-year follow-up period

Nadezhda V. Maksimova 1 ORCID, Anna V. Michenko 2, Olga A. Krasilnikova 3 ORCID, Ilya D. Klabukov 3 * ORCID, Igor Yu. Gadaev 4 ORCID, Michael E. Krasheninnikov 5 ORCID, Pavel A. Belkov 6, Aleksey V. Lyundup 5 ORCID

Cited by CrossRef: 4


1- Anjiki K, Matsumoto T, Kuroda Y, Fujita M, Hayashi S, Nakano N, Tsubosaka M, Kamenaga T, Takashima Y, Kikuchi K, Ikuta K, Onoi Y, Tachibana S, Suda Y, Wada K, Matsushita T, Kuroda R. Heterogeneous Cells as well as Adipose-Derived Stromal Cells in Stromal Vascular Fraction Contribute to Enhance Anabolic and Inhibit Catabolic Factors in Osteoarthritis. Stem Cell Rev and Rep. 2023;19(7):2407 [Crossref]
2- Trivanovic D, Volkmann N, Stoeckl M, Tertel T, Rudert M, Giebel B, Herrmann M. Enhancement of Immunosuppressive Activity of Mesenchymal Stromal Cells by Platelet-Derived Factors is Accompanied by Apoptotic Priming. Stem Cell Rev and Rep. 2023;19(3):713 [Crossref]
3- Krasilnikova O, Baranovskii D, Lyundup A, Shegay P, Kaprin A, Klabukov I. Stem and Somatic Cell Monotherapy for the Treatment of Diabetic Foot Ulcers: Review of Clinical Studies and Mechanisms of Action. Stem Cell Rev and Rep. 2022;18(6):1974 [Crossref]
4- Klabukov I, Yatsenko E, Baranovskii D. The effects of mesenchymal stromal cells and platelet-rich plasma treatments on cutaneous wound healing: ignoring the possibility of adverse events and side effects could compromise study results. Arch Dermatol Res. 2023;316(1) [Crossref]


As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate: 24% 
Publication fee: Free of charge